Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies
Open Access
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 48, 71-79
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Trials in Progress: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trials of a Nebulized Long-Acting Muscarinic Antagonist (Revefenacin) in Study Participants With Moderate to Very Severe COPDChest, 2016
- Trial in Progress: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial to Evaluate the Safety and Tolerability of a Nebulized Long-Acting Muscarinic Antagonist (Revefenacin) in Study Participants With COPDChest, 2016
- A review of nebulized drug delivery in COPDInternational Journal of Chronic Obstructive Pulmonary Disease, 2016
- Global burden of COPDRespirology, 2015
- The importance of inhaler devices in the treatment of COPDCOPD Research and Practice, 2015
- Long-acting muscarinic antagonistsExpert Review of Clinical Pharmacology, 2015
- In Vivo Pharmacological Characterization of TD-4208, a Novel Lung-Selective Inhaled Muscarinic Antagonist with Sustained Bronchoprotective Effect in Experimental Animal ModelsThe Journal of Pharmacology and Experimental Therapeutics, 2013
- Long-acting muscarinic receptor antagonists for the treatment of respiratory diseasePulmonary Pharmacology & Therapeutics, 2013
- Perceptions and Attitudes Toward the Use of Nebulized Therapy for COPD: Patient and Caregiver PerspectivesCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2013
- The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary diseaseAnnals of Physical and Rehabilitation Medicine, 2010